Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth

Related Experiment Video

Updated: Aug 19, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Shereen Ezzat1, Ping Huang, Alan Dackiw

  • 1Department of Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 15, 2005
PubMed

Insights

Targeting RET and FGFR4 with tyrosine kinase inhibitors shows promise for treating aggressive medullary thyroid cancer. Combined therapy with STI571 and PD173074 significantly suppressed tumor growth and proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Medullary thyroid cancer (MTC) is an aggressive malignancy with limited systemic treatment options.
  • Activating mutations in the RET proto-oncogene drive MTC development.
  • Novel therapeutic targets are needed for advanced or inoperable MTC.

Purpose of the Study:

  • To evaluate the efficacy of tyrosine kinase inhibitors (TKIs) targeting RET and FGFR4 in medullary thyroid cancer.
  • To investigate the potential of STI571 (RET inhibitor) and PD173074 (FGFR inhibitor) as monotherapies and in combination.
  • To assess the impact of these inhibitors on cancer cell proliferation, tumor growth, and invasiveness.

Main Methods:

  • In vitro studies using human TT medullary cancer cells.
  • In vivo xenograft studies in severe combined immunodeficiency (SCID) mice.
  • Assessment of RET and FGFR4 phosphorylation, cell proliferation, tumor growth, and invasiveness.

Main Results:

  • STI571 inhibited RET phosphorylation, cell proliferation, tumor growth, and invasiveness in vitro and in vivo.
  • PD173074 abrogated FGFR4 phosphorylation and suppressed cell proliferation and tumor growth.
  • Combination therapy with STI571 and PD173074 demonstrated superior inhibition of proliferation and tumor control compared to either agent alone.

Conclusions:

  • RET and FGFR4 are validated therapeutic targets in medullary thyroid cancer.
  • Combined inhibition of RET and FGFR4 offers a promising strategy for managing inoperable MTC.
  • Tyrosine kinase inhibitors represent a potential new class of systemic therapy for MTC.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...